Drug Trial Radar · NCT05716919
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Last checked: Nov 20, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
32
Actual
Start
Mar 9, 2023
Primary completion
Dec 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Machaon Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase I, Double blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'CG-745' Capsule in Healthy Male Volunteers
Conditions
- Hematologic Malignancy
- Solid Tumor
- Fibrosis
Interventions
IvaltinostatDrug
Ivaltinostat capsule
PlaceboOther
Placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Pharmacokinetic measures (Cmax, Cmax-ss)Time frame: up to 4 weeks
- Plasma Pharmacokinetic measures (AUC max, AUCmax-ss)Time frame: up to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.